Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm A Smith

Showing results (51-60 of 188) with videos related to

Pageof 19
Sort By:
Pediatric Blood & Cancer|June 29, 2010
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programChristopher L Morton, Peter J Houghton, E Anders Kolb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignanciesJun S Wei, Peter Johansson, Qing-Rong Chen, et al.
Pediatric Blood & Cancer|December 19, 2007
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing programRichard Lock, Hernan Carol, Peter J Houghton, et al.
Pediatric Blood & Cancer|April 11, 2007
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPeter J Houghton, Christopher L Morton, E Anders Kolb, et al.
Pediatric Blood & Cancer|February 23, 2008
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing programJohn M Maris, Joshua Courtright, Peter J Houghton, et al.
Pediatric Blood & Cancer|March 27, 2015
Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP)Peter J Houghton, Raushan T Kurmasheva, E Anders Kolb, et al.
Pediatric Blood & Cancer|May 4, 2023
In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenograftsJoanna Randall, Kathryn Evans, Ben Watts, et al.
Molecular Cancer Therapeutics|December 10, 2020
ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing ConsortiumPooja Hingorani, Michael E Roth, Yifei Wang, et al.
Pediatric Blood & Cancer|June 26, 2009
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing programHernan Carol, Richard Lock, Peter J Houghton, et al.
Pediatric Blood & Cancer|February 9, 2008
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing programMalcolm A Smith, Christopher L Morton, Doris A Phelps, et al.
Pageof 19

Showing results (51-60 of 188) with videos related to

Sort By:
Pageof 19
Pediatric Blood & Cancer|June 29, 2010
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programChristopher L Morton, Peter J Houghton, E Anders Kolb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignanciesJun S Wei, Peter Johansson, Qing-Rong Chen, et al.
Pediatric Blood & Cancer|December 19, 2007
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing programRichard Lock, Hernan Carol, Peter J Houghton, et al.
Pediatric Blood & Cancer|April 11, 2007
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPeter J Houghton, Christopher L Morton, E Anders Kolb, et al.
Pediatric Blood & Cancer|February 23, 2008
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing programJohn M Maris, Joshua Courtright, Peter J Houghton, et al.
Pediatric Blood & Cancer|March 27, 2015
Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP)Peter J Houghton, Raushan T Kurmasheva, E Anders Kolb, et al.
Pediatric Blood & Cancer|May 4, 2023
In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenograftsJoanna Randall, Kathryn Evans, Ben Watts, et al.
Molecular Cancer Therapeutics|December 10, 2020
ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing ConsortiumPooja Hingorani, Michael E Roth, Yifei Wang, et al.
Pediatric Blood & Cancer|June 26, 2009
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing programHernan Carol, Richard Lock, Peter J Houghton, et al.
Pediatric Blood & Cancer|February 9, 2008
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing programMalcolm A Smith, Christopher L Morton, Doris A Phelps, et al.
Pageof 19